Coya Therapeutics (NASDAQ: COYA) reported third-quarter 2025 results highlighting strong operational momentum, new clinical milestones, and a cash runway extending into the second half of 2027—positioning the company for a catalyst-rich year ahead.
Pipeline Progress Driving Near-Term Catalysts
Coya’s Treg-enhancing platform continues to advance across neurodegenerative indications. The company launched the ALSTARS Phase 2 trial of COYA 302 in ALS, following FDA IND acceptance, and received a $4.2 million milestone payment from strategic partner Dr. Reddy’s Laboratories. Enrollment is expected to begin in the coming weeks, with first-patient dosing to trigger another $4.2 million payment.
“We believe the recent financing, which included participation from new and existing investors, is a testament to their confidence in our programs,” said CEO Arun Swaminathan, Ph.D. “With this financing, we anticipate extending our runway into 2H 2027 and past the ALSTARS topline readout.”
“With the start of the ALSTARS Phase 2 trial, and as up to 25 sites are initiated, we expect enrollment and dosing to begin soon,” added CMO Dr. Fred Grossman. “We also look forward to the FTD data analysis and expect to submit an IND for a Phase 2 FTD trial later this year.”
Key Upcoming Milestones
- First ALS patient enrollment and dosing in the ALSTARS Phase 2 trial
- $4.2M milestone payment upon first-patient dosing
- ALS biomarker data publication, including Neurofilament Light Chain and oxidative stress markers
- Preclinical COYA 303 data on systemic and CNS inflammation
- Top-line data from the investigator-initiated FTD trial combining LD IL-2 + CTLA4-Ig
- IND submission for FTD by year-end
Financial Highlights
Coya reported Q3 collaboration revenue of $3.6 million, primarily from IND-related milestones. R&D expenses totaled $2.9 million versus $2.2 million last year, reflecting advancing clinical activity. Net loss improved to $2.1 million, compared to $4.0 million in Q3 2024. The company ended the quarter with $28.1 million in cash, strengthened by a $23 million upsized offering.
Positioned for Value-Creating Inflection Points
With multiple clinical readouts, IND submissions, and milestone payments expected in the next several quarters, Coya is entering a period of heightened execution and visibility. The company’s focus on Treg biology continues to define its leadership in addressing neuroinflammation in ALS, FTD, and Alzheimer’s disease.
The post Coya Therapeutics Extends Runway Into 2027 and Readies for Multiple Clinical Catalysts appeared first on PRISM MarketView.
